RESUMO
Automated features available in cardiac implantable electronic devices continue to increase in number and complexity. These features are frequently confused with device malfunction and often result in unnecessary clinical attention. This review will serve as an update to some of the more commonly-encountered features discussed in terms of the behavior they exhibit.
Assuntos
Algoritmos , Arritmias Cardíacas/terapia , Estimulação Cardíaca Artificial , Desfibriladores Implantáveis , Cardioversão Elétrica/instrumentação , Eletrocardiografia/instrumentação , Marca-Passo Artificial , Tecnologia de Sensoriamento Remoto/instrumentação , Processamento de Sinais Assistido por Computador , Potenciais de Ação , Arritmias Cardíacas/diagnóstico , Arritmias Cardíacas/fisiopatologia , Automação , Estimulação Cardíaca Artificial/efeitos adversos , Cardioversão Elétrica/efeitos adversos , Frequência Cardíaca , Humanos , Valor Preditivo dos Testes , Desenho de Prótese , Falha de Prótese , Reprodutibilidade dos Testes , Resultado do TratamentoRESUMO
Is there a full-blown stroke epidemic and a growing ischemic heart disease (IHD) epidemic in Sub-Saharan Africa? We aim to further understand the evolution of stroke and IHD in Sub-Saharan Africa with an analysis of the most recent Global Burden of Disease estimates of mortality for men of Sub-Saharan African descent in Africa and in the Caribbean and a review of recent studies found on PubMed and reference lists of published articles. Stroke is the most important cause of cardiovascular disease mortality in men aged 60-64 years in Africa and the Caribbean, but death rates and rank may vary by region. Ischemic heart disease is a leading cause in the Caribbean.
Assuntos
População Negra/estatística & dados numéricos , Doenças Cardiovasculares/etnologia , Doenças Cardiovasculares/mortalidade , Adulto , África Subsaariana/epidemiologia , Idoso , Região do Caribe/epidemiologia , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
Left bundle branch pacing (LBBP) is a novel technique that has emerged as an alternative method for conduction system pacing. As a new modality, this procedure may carry complications that are yet to be explored. This report describes a case of injury to the left bundle branch during deep septal lead implantation for LBBP.
RESUMO
Atrial fibrillation (AF) is the most common sustained arrhythmia, affecting between 3 and 6 million people in the United States. It is associated with a reduced quality of life and increased risk of stroke, cognitive decline, heart failure and death. Black patients have a lower prevalence of AF than White patients but are more likely to suffer worse outcomes with the disease. It is important that stakeholders understand the disproportionate burden of disease and management gaps that exists among Black patients living with AF. Appropriate treatments, including aggressive risk factor control, early referral to cardiovascular specialists and improving healthcare access may bridge some of the gaps in management and improve outcomes.
RESUMO
Background: The development of coronavirus disease 2019 (COVID-19) vaccine-associated myocarditis has been reported. Most of the reported cases are mild, with quick clinical recovery and excellent short-term outcomes. Cases of COVID-19 vaccine-associated myocarditis presenting with sustained ventricular tachycardia (VT) are rare. Case Description: A 46-year-old male patient with no prior cardiac history presented following two episodes of syncope. Two days earlier, he had received his second dose of COVID-19 mRNA vaccine (Pfizer)-first dose was administered three weeks earlier. He had an episode of VT while in the emergency room. His cardiac magnetic resonance imaging (MRI) findings were consistent with myocarditis. He was eventually diagnosed with COVID-19 vaccine-associated myocarditis after all other work up were unremarkable [echocardiogram, coronary angiogram, diagnostic electrophysiology study and later 18F-fluorodeoxyglucose (FDG) metabolism cardiac sarcoid positron emission tomography (PET) study]. An implantable cardiac monitor was implanted to monitor for recurrence of VT. Seven months after initial presentation, he had recurrent VT and he underwent implantation of an implantable cardioverter defibrillator (ICD). He has received appropriate ICD therapies on account of recurrent VT and he is currently maintained on an antiarrhythmic medication. Conclusions: Excellent short-term outcomes have been reported in patients with COVID-19 vaccine associated myocarditis. Our case shows that long-term outcomes may not be benign in everyone, particularly in those who develop myocardial scar.
RESUMO
Sick sinus syndrome (SSS) is a condition of the sinoatrial node that arises from a constellation of aberrant rhythms, resulting in reduced pacemaker activity and impulse transmission. According to the World Health Organization, pulmonary hypertension (PH) is defined by a mean pulmonary arterial pressure of >25 mmHg at rest, measured during right heart catheterization. It can result in right atrial remodeling, which may predispose the patient to sinus node dysfunction. This study sought to estimate the impact of PH on clinical outcomes of hospitalizations with SSS. The U.S. National Inpatient Sample database from 2016-2019 was searched for hospitalized adult patients with SSS as a principal diagnosis with and without PH as a secondary diagnosis using the International Classification of Diseases, Tenth Revision, codes. The primary outcome was inpatient mortality. The secondary outcomes were acute kidney injury (AKI), cardiogenic shock (CS), cardiac arrest, rates of pacemaker insertion, total hospital charges (THCs), and length of stay (LOS). Multivariate regression analysis was used to adjust for confounders. A total of 181,230 patients were admitted for SSS; 8.3% (14,990) had underlying PH. Compared to patients without PH, patients admitted with coexisting PH had a statistically significant increase in mortality (95% confidence interval, 1.21-2.32; P = .002), AKI (P < .001), CS (P = .004), THC (P = .037), and LOS (P < .001). In conclusion, patients admitted primarily for SSS with coexisting PH had a statistically significant increase in mortality, AKI, CS, THC, and LOS. Additional studies geared at identifying and addressing the underlying etiologies for PH in this population may be beneficial in the management of this patient group.
RESUMO
We aimed to determine whether newly diagnosed atrial fibrillation (AF) predicted cardiovascular events and death after myocardial infarction (AMI) in a large nationwide cohort of patients. All Medicare beneficiaries aged >65 years who were discharged alive after a diagnosis of AMI between January 1, 2007 and December 31, 2008 were identified. Main exposure was a diagnosis of AF during admission or within 90 days after discharge. Primary outcome was a composite of recurrent AMI, stroke and all-cause mortality. Secondary outcomes were each of recurrent AMI, stroke and all-cause mortality. We used Cox proportional hazards regression to assess the relationship between AF and time-to-event outcomes with follow up ending at 3 years. Of 184,980 patients, 9.1 % had AF; 40.6 % were male; 82.8 % were non-Hispanic whites. Mean age was 79.1 ± 8.1 years. Overall, 15.7 % had subsequent AMI, 5.7 % had stroke and 43.9 % died during a mean follow up of 26.4 months. AF was associated with a significantly increased risk of the primary outcome (Hazard ratio (HR) = 1.10; 95 % confidence interval (CI): 1.07-1.12). AF was also separately associated with significantly increased risk of recurrent AMI (HR = 1.09; 95 % CI: 1.04-1.14), stroke (HR = 1.29; 95 % CI: 1.21-1.37), and death (HR = 1.09; 95 % CI: 1.06-1.12). Neither age, race nor sex modified the effects of AF on primary or secondary outcomes. In conclusion, AF is a significant predictor of adverse cardiovascular outcomes and mortality after AMI. Further studies are needed to understand mechanisms by which AF alters outcomes in survivors of AMI.
Assuntos
Fibrilação Atrial , Infarto do Miocárdio , Acidente Vascular Cerebral , Humanos , Idoso , Masculino , Estados Unidos/epidemiologia , Idoso de 80 Anos ou mais , Feminino , Fibrilação Atrial/diagnóstico , Fibrilação Atrial/epidemiologia , Fibrilação Atrial/complicações , Prognóstico , Medicare , Fatores de Risco , Estudos Retrospectivos , Infarto do Miocárdio/diagnóstico , Infarto do Miocárdio/terapia , Infarto do Miocárdio/complicações , Acidente Vascular Cerebral/diagnóstico , Acidente Vascular Cerebral/terapia , Acidente Vascular Cerebral/complicaçõesRESUMO
Patients with aortic stenosis who undergo transcatheter aortic valve replacement/transcatheter aortic valve implantation (TAVR/TAVI) experience a high incidence of pre-existing atrial fibrillation (pre-AF) and new-onset atrial fibrillation (NOAF) post-operatively. This systematic review and meta-analysis aimed to update current evidence concerning the incidence of 30-day mortality, stroke, acute kidney injury (AKI), length of stay (LOS), and early/late bleeding in patients with NOAF or pre-AF who undergo TAVR/TAVI. PubMed, Google Scholar, JSTOR, Cochrane Library, and Web of Science were searched for studies published between January 2012 and December 2020 reporting the association between NOAF/pre-AF and clinical complications after TAVR/TAVI. A total of 15 studies including 158,220 adult patients with TAVI/TAVR and NOAF or pre-AF were identified. Compared to patients in sinus rhythm, patients who developed NOAF had a higher risk of 30-day mortality, AKI, early bleeding events, extended LOS, and stroke after TAVR/TAVI (odds ratio [OR]: 3.18 [95% confidence interval [CI] 1.58, 6.40]) (OR: 3.83 [95% CI 1.18, 12.42]) (OR: 1.70 [95% CI 1.05, 2.74]) (OR: 13.96 [95% CI, 6.41, 30.40]) (OR: 2.51 [95% CI 1.59, 3.97], respectively). Compared to patients in sinus rhythm, patients with pre-AF had a higher risk of AKI and early bleeding episodes after TAVR/TAVI (OR: 2.43 [95% CI 1.10, 5.35]) (OR: 17.41 [95% CI 6.49, 46.68], respectively). Atrial fibrillation is associated with a higher risk of all primary and secondary outcomes. Specifically, NOAF but not pre-AF is associated with a higher risk of 30-day mortality, stroke, and extended LOS after TAVR/TAVI.
RESUMO
The impact of atrial fibrillation (AF) on the hospitalization outcomes in patients ≥ 60 years of age with implantable cardioverter defibrillators (ICD) is not well studied. We queried the National Inpatient Sample database for all patients aged ≥ 60 who had a history of ICD placement, and were admitted with a primary diagnosis of heart failure (HF) during the years 2016-2017. Patients were stratified into 2 groups based on their history of AF. The primary outcome of the study was all-cause in-hospital mortality. Secondary outcomes included cardiogenic shock, myocardial infarction (MI), ventricular fibrillation (VF), stroke and acute kidney injury (AKI). The association between different age strata and outcomes was investigated. The hospitalization outcomes were modeled using logistic regression. A total of 178,045 patients were included, of whom 56.2% had AF. AF correlated with increased mortality (A-OR 1.22 (95% CI: 1.06-1.4), p=0.005), cardiogenic shock (A-OR 1.21 (95%CI: 1.08-1.36), p<0.001), AKI (A-OR 1.12 (95%CI: 1.06-1.17), p<0.001 and lower risk for MI (A-OR 0.79 (95% CI: 0.68-0.9), p<0.001. There was no correlation between AF and risk for VF or stroke. A significant correlation between AF and higher risk for mortality, cardiogenic shock and AKI was demonstrated in ages ≤ 75, ≤ 75, and ≤ 80 years, respectively. In contrast, a significant correlation between AF and lower risk for MI is only demonstrated at age > 70 years. We conclude that AF is an independent predictor for increased all-cause in-hospital mortality and cardiogenic shock. Such risk is influenced by age.
Assuntos
Fibrilação Atrial/epidemiologia , Desfibriladores Implantáveis , Insuficiência Cardíaca/terapia , Mortalidade Hospitalar , Injúria Renal Aguda/epidemiologia , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Morte Súbita Cardíaca/prevenção & controle , Feminino , Insuficiência Cardíaca/epidemiologia , Hospitalização , Humanos , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/epidemiologia , Choque Cardiogênico/epidemiologia , Acidente Vascular Cerebral/epidemiologia , Fibrilação Ventricular/epidemiologiaRESUMO
BACKGROUND: Wider availability of continuous rhythm monitoring has made feasible the incorporation of metrics of atrial fibrillation (AF) burden and duration into the decision to initiate anticoagulation. However, the relationship between thresholds of burden and duration and underlying risk factors at which anticoagulation should be considered remains unclear. OBJECTIVE: The purpose of this study was to evaluate the relationships of these metrics with each other and the outcome of stroke/transient ischemic attack (TIA). METHODS: We identified patients with cardiovascular implantable electronic devices (CIEDs) with atrial leads who had at least 1 interrogation in 2016 demonstrating nonpermanent AF and were not receiving oral anticoagulation (OAC). We evaluated the relationship between burden (ie, percentage of time spent in AF), the longest single episode of AF, and risk factors (ie, CHA2DS2-VASc score) in predicting risk of stroke/TIA. RESULTS: The study included 384 patients with mean follow-up of 3.2 ± 0.8 years and incidence of stroke/TIA of 14.8% during follow-up (â¼4.6% per year). The burden of AF and the duration of longest episode demonstrated a significant positive correlation to each other but not CHA2DS2-VASc score. Importantly, although the CHA2DS2-VASc score was predictive of stroke/TIA, neither burden nor duration was associated with stroke/TIA. CONCLUSION: Among patients with CIED-detected AF not receiving OAC, the amount of AF (measured by either burden or duration) does not seem to significantly impact stroke risk, whereas CHA2DS2-VASc score does. These data suggest that among patients with CIED-detected AF, once AF occurs, stroke risk seems to be predominantly driven by underlying risk factors.
Assuntos
Anticoagulantes/uso terapêutico , Fibrilação Atrial/diagnóstico , Eletrocardiografia Ambulatorial/instrumentação , Frequência Cardíaca/fisiologia , AVC Isquêmico/etiologia , Medição de Risco/métodos , Idoso , Fibrilação Atrial/complicações , Fibrilação Atrial/tratamento farmacológico , Desenho de Equipamento , Estudos de Viabilidade , Feminino , Seguimentos , Humanos , Incidência , AVC Isquêmico/epidemiologia , AVC Isquêmico/prevenção & controle , Masculino , Estudos Retrospectivos , Estados Unidos/epidemiologiaRESUMO
BACKGROUND: Current risk prediction models in acute coronary syndrome (ACS) patients undergoing PCI are mathematically complex. This study was undertaken to assess the accuracy of a modified CHA2DS2-VASc score, comprised of easily accessible clinical factors in predicting adverse events. METHODS: The National Inpatient Sample (NIS) was queried for ACS patients who underwent PCI between 2010 and 2014. We developed a modified CHA2DS2-VASc score for risk prediction in ACS patients. Multivariate mixed effect logistic regression was utilized to study the adjusted risk for adverse outcomes based on the score. The primary outcome evaluated was in-hospital mortality. Secondary outcomes assessed were stroke, respiratory failure, acute kidney injury, all-cause bleeding, pacemaker insertion, vascular complications, length of stay and cost. RESULTS: There were 252,443 patients admitted with ACS included. Mean age was 62 ± 12 years. The mean CH3A2DS-VASc score was 1.6 ± 1.6. The in-hospital mortality rate was 2.5%. CH3A2DS-VASc score was highly correlated with increased rate of mortality and all secondary outcomes. ROC curve analysis for association of CH3A2DS-VASc score with mortality demonstrates that area under the curve (AUC) = 0.83 (95%C: 0.82-0.84). Stepwise increases in CH3A2DS-VASc score correlated with incremental risk, and total score was an independent predictor of mortality (adjusted OR: 1.99 (95%CI: 1.96-2.03) p < 0.001) and all secondary outcomes. CONCLUSION: This study supports the applicability of the CH3A2DS-VASc score as an accurate risk prediction model for ACS patients undergoing PCI and could supplant more complicated models for quality assurance.
RESUMO
OBJECTIVE: To investigate the association between fluoroquinolones use and development of aortopathy. METHODS: A systematic review and meta-analysis was conducted following PRISMA and MOOSE guidelines for reporting systematic reviews of observational studies. Multiple databases were searched and two authors independently screened studies for eligibility. Newcastle Ottawa scale was used to assessed the quality of included studies. Primary outcome of interest was development of aortic aneurysm or dissection among fluoroquinolones users in comparison to non-users. An inverse variance model meta-analysis was used to pool odds ratio or hazards ratio from included studies to calculate the overall effect estimate. Pre specified subgroups analyses were also conducted to explore sources of heterogeneity. RESULTS: Three observational studies that enrolled 941,639 subjects met the inclusion criteria and were included in the final analysis. All studies were of a good methodological quality. Current use of fluoroquinolones, defined as within 60â¯days from development of the primary outcome, was associated with significantly elevated risk of developing aortic aneurysm and/or dissection in comparison to controls, (ORâ¯=â¯2.04; 95% CI [1.67, 2.48]). There was only a mild degree of between study heterogeneity, I2â¯=â¯33%. The association remains robust among all subgroups analyses. CONCLUSION: Our findings indicate that current fluoroquinolone use was significantly associated with increased risk of aortic aneurysm and dissection. Health care providers need to be aware of this serious association and use fluoroquinolones judiciously in order to minimize the risk of the serious sequela of aortopathy.
Assuntos
Aneurisma Aórtico/induzido quimicamente , Dissecção Aórtica/induzido quimicamente , Fluoroquinolonas/efeitos adversos , Medição de Risco , Dissecção Aórtica/epidemiologia , Antibacterianos/efeitos adversos , Aneurisma Aórtico/epidemiologia , Infecções Bacterianas/tratamento farmacológico , Saúde Global , Humanos , Incidência , Fatores de RiscoRESUMO
BACKGROUND: The relationship between competitive sports and atrial fibrillation (AF) is controversial. We aimed to systematically evaluate and summarize all published observational data on the association between competitive sports and AF. METHODS AND RESULTS: We searched PubMed, EMBASE, Scopus and SportDiskus for all observational studies that assessed the risk of AF among athletes involved in competitive sports. Data were extracted and pooled odds ratios (OR) were calculated using random effects models. Six cohort studies and 2 case-control studies with a total of 9113 subjects were included in our meta-analysis. Pooled analyses showed an increased risk of incident and prevalent AF among athletes compared to the general population (ORâ¯=â¯1.64 [95% confidence interval (CI): 1.10-2.43]). Age-stratified analysis revealed an effect modification with age. Studies enrolling younger adults (<54â¯years) had an increased risk of AF among athletes compared to controls (ORâ¯=â¯1.96 [95% CI: 1.06-3.65]), but this association was not seen among older adults ≥54â¯years (ORâ¯=â¯1.41 [95% CI: 0.81-2.44], pâ¯=â¯0.23). CONCLUSION: Athletes have an increased risk of AF compared to the general population. Age appears to modify the risk of AF in athletes.